ArticleLipids in health and disease2003
Endocannabinoid signalling in the blood of patients with schizophrenia.
Article in Lipids in health and disease, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it, 266 citations in OpenAlex.
- Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.JAMA psychiatry · 2019Pooled it
- Trial
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.Translational psychiatry · 2012Trial
- Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication.European archives of psychiatry and clinical neuroscience · 2025Article
- Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.Current pharmaceutical design · 2025Review
- Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.International journal of molecular sciences · 2024Review
- Selective alterations of endocannabinoid system genes expression in obsessive compulsive disorder.Translational psychiatry · 2024Article
- Peripheral Endocannabinoid Components and Lipid Plasma Levels in Patients with Resistant Migraine and Co-Morbid Personality and Psychological Disorders: A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- Article
- The Modulated Role ofPathogens (Basel, Switzerland) · 2023Article
- Inhibitors of Endocannabinoids' Enzymatic Degradation as a Potential Target of the Memory Disturbances in an Acute N-Methyl-D-Aspartate (NMDA) Receptor Hypofunction Model of Schizophrenia in Mice.International journal of molecular sciences · 2023Article
- Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder.International journal of molecular sciences · 2023Article
- The Inflammatory Signals Associated with Psychosis: Impact of Comorbid Drug Abuse.Biomedicines · 2023Review
- Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients.Addiction biology · 2022Article
- Cannabinoids, reward processing, and psychosis.Psychopharmacology · 2022Review
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
- Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia.Advances in experimental medicine and biology · 2022Article
- Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.Biomolecules · 2020Review
- Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.Biological psychiatry · 2020Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo test the hypothesis that schizophrenia might be associated with alterations of the endogenous cannabinoid system in human blood.
resultsBlood from 20 healthy volunteers and 12 patients with schizophrenia, 5 of which both before and after a successful antipsychotic treatment, was analysed for: 1) the amounts of the endocannabinoid anandamide; 2) the levels of cannabinoid CB1 and CB2 receptor mRNAs, and 3) the levels of the mRNA encoding the enzyme fatty acid amide hydrolase (FAAH), responsible for anandamide degradation. The amounts of anandamide were significantly higher in the blood of patients with acute schizophrenia than in healthy volunteers (7.79 +/- 0.50 vs. 2.58 +/- 0.28 pmol/ml). Clinical remission was accompanied by a significant decrease of the levels of anandamide (3.88 +/- 0.72 pmol/ml) and of the mRNA transcripts for CB2 receptors and FAAH.
conclusionThese findings indicate that endocannabinoid signalling might be altered during the acute phase of schizophrenia not only in the central nervous system but also in the blood. These changes might be related to the several immunological alterations described in schizophrenia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.